Ascendis Pharma A/S (ASND) is a Biotechnology company in the Healthcare sector, currently trading at $249.84. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ASND = $328.76 (+31.6% from the current price, the stock appears undervalued). Analyst consensus target is ASND = $287 (+14.9% upside).
Valuation: ASND trades at a trailing Price-to-Earnings (P/E) of -54.5 (S&P 500 average ~25).
Financials: revenue is $692M, +182.6%/yr average growth. Net income is $219M (loss), growing at +27%/yr. Net profit margin is -31.7% (negative). Gross margin is 85.1% (+8.8 pp trend).
Balance sheet: total debt is $871M with negative equity of -$163M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.04 (adequate). Debt-to-assets is 66.9%. Total assets: $1.3B.
Analyst outlook: 22 / 24 analysts rate ASND as buy (92%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 25/100 (Fail), Moat 76/100 (Pass), Future 88/100 (Pass), Income 10/100 (Fail).
